{"id":2345,"date":"2020-06-15T00:00:00","date_gmt":"2020-06-15T00:00:00","guid":{"rendered":"http:\/\/centogene.vl22350.dinaserver.com\/2345"},"modified":"2020-06-15T00:00:00","modified_gmt":"2020-06-15T00:00:00","slug":"a-centogene-divulga-os-resultados-financeiros-e-o-progresso-corporativo-do-primeiro-trimestre-de-2020","status":"publish","type":"post","link":"https:\/\/www.centogene.com\/pt\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\/","title":{"rendered":"A CENTOGENE divulga os resultados financeiros e o progresso corporativo do primeiro trimestre de 2020."},"content":{"rendered":"<p>Cambridge, MA, EUA e Rostock\/Berlim, Alemanha, 15 de junho de 2020 (Globe Newswire) \u2013 A Centogene NV (Nasdaq: CNTG), empresa em fase comercial focada em doen\u00e7as raras que transforma dados cl\u00ednicos e gen\u00e9ticos do mundo real em informa\u00e7\u00f5es acion\u00e1veis para pacientes, m\u00e9dicos e empresas farmac\u00eauticas, divulgou hoje uma atualiza\u00e7\u00e3o sobre seu progresso corporativo e apresentou seus resultados financeiros referentes ao trimestre encerrado em 31 de mar\u00e7o de 2020.<\/p>\n<ul>\n<li>Receita de \u20ac 12,1 milh\u00f5es, um aumento de 13% em compara\u00e7\u00e3o com o trimestre encerrado em 31 de mar\u00e7o de 2019.<\/li>\n<li>Expans\u00e3o cont\u00ednua da plataforma global propriet\u00e1ria para doen\u00e7as raras, com aproximadamente 3 bilh\u00f5es de pontos de dados ponderados de mais de 530.000 pacientes representando 120 pa\u00edses diferentes, em 31 de mar\u00e7o de 2020.<\/li>\n<li>Mais de 60 programas de biomarcadores, dos quais mais de 25 (abrangendo mais de 22 doen\u00e7as) j\u00e1 conclu\u00edram a primeira valida\u00e7\u00e3o com espectrometria de massa at\u00e9 31 de mar\u00e7o de 2020.<\/li>\n<li>Amplia\u00e7\u00e3o dos nossos testes de COVID-19 e in\u00edcio da produ\u00e7\u00e3o e distribui\u00e7\u00e3o de um kit de coleta de amostras, o CentoSwab\u2122, para apoiar os esfor\u00e7os globais no combate \u00e0 pandemia.<\/li>\n<\/ul>\n<p>O Prof. Arndt Rolfs, CEO da CENTOGENE, afirmou: \u201cDurante o primeiro trimestre de 2020, mantivemos o foco em nosso neg\u00f3cio principal, que \u00e9 fornecer diagn\u00f3sticos m\u00e9dicos precisos e acelerar o desenvolvimento de medicamentos para doen\u00e7as heredit\u00e1rias raras, ao mesmo tempo em que tomamos medidas importantes para operar nossos neg\u00f3cios de forma eficaz durante a COVID-19 e apoiar os esfor\u00e7os mais amplos para combater essa pandemia. Temos o prazer de anunciar um crescimento de receita de 131% no primeiro trimestre de 2020, impulsionado pela melhoria cont\u00ednua dos neg\u00f3cios em nossos segmentos de Produtos Farmac\u00eauticos e Diagn\u00f3sticos.\u201d<\/p>\n<p>O Prof. Arndt Rolfs prosseguiu: \u201cEnquanto continuamos a operar em um ambiente de COVID-19, temos o prazer de informar que, embora nossas a\u00e7\u00f5es iniciais r\u00e1pidas tenham permitido que 751.000 funcion\u00e1rios trabalhassem em casa, recentemente conseguimos trazer de volta quase toda a nossa equipe ao escrit\u00f3rio, implementando testes regulares. Al\u00e9m disso, aproveitamos ainda mais nossa expertise em diagn\u00f3stico para desenvolver e oferecer uma solu\u00e7\u00e3o de teste para SARS-CoV-2 para pacientes em todo o mundo \u2013 come\u00e7ando com o sistema de coleta de amostras &#039;CentoSwab\u2122&#039; e terminando com o aplicativo desenvolvido pela CENTOGENE para cadastro de pacientes e emiss\u00e3o de laudos m\u00e9dicos. Esperamos que essa solu\u00e7\u00e3o de diagn\u00f3stico ajude as comunidades globais a come\u00e7arem a retornar a uma nova normalidade e a prevenir novos surtos. Com a pandemia de COVID-19 continuando a se espalhar pelo mundo, come\u00e7amos a sentir seu impacto negativo em nossos neg\u00f3cios atuais, mas esperamos que nossos testes comerciais para COVID-19 ajudem a compensar esse impacto negativo.\u2018<\/p>\n<h2 class=\"h3\">Resposta \u00e1gil \u00e0 COVID-19 e continuidade das opera\u00e7\u00f5es de diagn\u00f3stico de doen\u00e7as raras.<\/h2>\n<h5>Liderando a implementa\u00e7\u00e3o de capacidades sustent\u00e1veis de testagem para COVID-19<\/h5>\n<p>Em mar\u00e7o de 2020, a CENTOGENE anunciou o in\u00edcio de seus testes para COVID-19. Come\u00e7ando com funcion\u00e1rios e trabalhadores essenciais em Rostock, Alemanha, a empresa expandiu a oferta de testes para lares de idosos e estudantes do ensino m\u00e9dio em toda a Alemanha. Desde maio de 2020, a empresa oferece seus testes para o resto do mundo. Al\u00e9m disso, a CENTOGENE garantiu os reagentes e suprimentos necess\u00e1rios, como o CentoSwab\u2122, para dar suporte \u00e0 log\u00edstica e ao diagn\u00f3stico r\u00e1pido da COVID-19 desde abril de 2020.<\/p>\n<h5>Aquisi\u00e7\u00e3o do Laborat\u00f3rio de Hamburgo para expandir a capacidade de testes.<\/h5>\n<p>Em abril de 2020, a CENTOGENE anunciou a abertura de um novo laborat\u00f3rio em Hamburgo, Alemanha, para aumentar sua capacidade de testes para o v\u00edrus COVID-19. O laborat\u00f3rio de Rostock continuar\u00e1 focado nas atividades principais da empresa, que s\u00e3o doen\u00e7as heredit\u00e1rias raras, e em seus esfor\u00e7os de pesquisa no desenvolvimento de biomarcadores.<\/p>\n<h5><strong>Contato com a m\u00eddia<\/strong><\/h5>\n<p>CENTOGENE<br \/> Sun Kim<br \/> Diretor(a) de Estrat\u00e9gia e Rela\u00e7\u00f5es com Investidores<br \/> <a href=\"mailto:investor.relations@centogene.com\" title=\"Escreva um e-mail\">investor.relations(at)centogene(dot)com&nbsp;<\/a><\/p>\n<p> Bridie Lawlor<br \/> Consultoria FTI<br \/> +1.917.929.5684<br \/> <a href=\"mailto:bridie.lawlor@fticonsulting.com\" title=\"Escreva um e-mail\">bridie.lawlor(at)fticonsulting(dot)com<\/a><br \/> &nbsp;<\/p>","protected":false},"excerpt":{"rendered":"<p>Durante o primeiro trimestre de 2020, mantivemos o foco em nossa atividade principal, que \u00e9 fornecer diagn\u00f3sticos m\u00e9dicos precisos e acelerar o desenvolvimento de medicamentos para doen\u00e7as heredit\u00e1rias raras, ao mesmo tempo em que tomamos medidas importantes para operar nossos neg\u00f3cios de forma eficaz durante a COVID-19 e apoiar os esfor\u00e7os mais amplos para enfrentar essa pandemia.<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2345","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CENTOGENE Reports First-Quarter 2020 Financial Results and Corporate Progress | CENTOGENE<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.centogene.com\/pt\/a-centogene-divulga-os-resultados-financeiros-e-o-progresso-corporativo-do-primeiro-trimestre-de-2020\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CENTOGENE Reports First-Quarter 2020 Financial Results and Corporate Progress | CENTOGENE\" \/>\n<meta property=\"og:description\" content=\"During the first quarter of 2020, we continued our focus on our core business of providing precise medical diagnosis of and accelerating drug development for rare hereditary diseases, while taking important steps to operate our business effectively during COVID-19 and support broader efforts to address this pandemic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.centogene.com\/pt\/a-centogene-divulga-os-resultados-financeiros-e-o-progresso-corporativo-do-primeiro-trimestre-de-2020\/\" \/>\n<meta property=\"og:site_name\" content=\"CENTOGENE\" \/>\n<meta property=\"article:published_time\" content=\"2020-06-15T00:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"740\" \/>\n\t<meta property=\"og:image:height\" content=\"416\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"admincg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"admincg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\\\/\"},\"author\":{\"name\":\"admincg\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\"},\"headline\":\"CENTOGENE Reports First-Quarter 2020 Financial Results and Corporate Progress\",\"datePublished\":\"2020-06-15T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\\\/\"},\"wordCount\":552,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\\\/\",\"name\":\"CENTOGENE Reports First-Quarter 2020 Financial Results and Corporate Progress | CENTOGENE\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\"},\"datePublished\":\"2020-06-15T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.centogene.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CENTOGENE Reports First-Quarter 2020 Financial Results and Corporate Progress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"name\":\"CENTOGENE\",\"description\":\"Guiding Precision Medicine\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.centogene.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\",\"name\":\"CENTOGENE\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"contentUrl\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"width\":246,\"height\":246,\"caption\":\"CENTOGENE\"},\"image\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/centogene\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UClZxtN_laC1_ZtCdxkasdPQ\",\"https:\\\/\\\/www.instagram.com\\\/_centogene_\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\",\"name\":\"admincg\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/pt\\\/author\\\/admincg\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CENTOGENE divulga resultados financeiros e progresso corporativo do primeiro trimestre de 2020 | CENTOGENE","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.centogene.com\/pt\/a-centogene-divulga-os-resultados-financeiros-e-o-progresso-corporativo-do-primeiro-trimestre-de-2020\/","og_locale":"pt_BR","og_type":"article","og_title":"CENTOGENE Reports First-Quarter 2020 Financial Results and Corporate Progress | CENTOGENE","og_description":"During the first quarter of 2020, we continued our focus on our core business of providing precise medical diagnosis of and accelerating drug development for rare hereditary diseases, while taking important steps to operate our business effectively during COVID-19 and support broader efforts to address this pandemic.","og_url":"https:\/\/www.centogene.com\/pt\/a-centogene-divulga-os-resultados-financeiros-e-o-progresso-corporativo-do-primeiro-trimestre-de-2020\/","og_site_name":"CENTOGENE","article_published_time":"2020-06-15T00:00:00+00:00","og_image":[{"width":740,"height":416,"url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp","type":"image\/webp"}],"author":"admincg","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"admincg","Est. tempo de leitura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.centogene.com\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\/#article","isPartOf":{"@id":"https:\/\/www.centogene.com\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\/"},"author":{"name":"admincg","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b"},"headline":"CENTOGENE Reports First-Quarter 2020 Financial Results and Corporate Progress","datePublished":"2020-06-15T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.centogene.com\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\/"},"wordCount":552,"commentCount":0,"publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"articleSection":["Uncategorized"],"inLanguage":"pt-BR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.centogene.com\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.centogene.com\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\/","url":"https:\/\/www.centogene.com\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\/","name":"CENTOGENE divulga resultados financeiros e progresso corporativo do primeiro trimestre de 2020 | CENTOGENE","isPartOf":{"@id":"https:\/\/www.centogene.com\/#website"},"datePublished":"2020-06-15T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.centogene.com\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.centogene.com\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.centogene.com\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.centogene.com\/"},{"@type":"ListItem","position":2,"name":"CENTOGENE Reports First-Quarter 2020 Financial Results and Corporate Progress"}]},{"@type":"WebSite","@id":"https:\/\/www.centogene.com\/#website","url":"https:\/\/www.centogene.com\/","name":"CENTOGENE","description":"Orientando a Medicina de Precis\u00e3o","publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.centogene.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/www.centogene.com\/#organization","name":"CENTOGENE","url":"https:\/\/www.centogene.com\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","contentUrl":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","width":246,"height":246,"caption":"CENTOGENE"},"image":{"@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/centogene","https:\/\/www.youtube.com\/channel\/UClZxtN_laC1_ZtCdxkasdPQ","https:\/\/www.instagram.com\/_centogene_\/"]},{"@type":"Person","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b","name":"admincg","url":"https:\/\/www.centogene.com\/pt\/author\/admincg\/"}]}},"_links":{"self":[{"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/posts\/2345","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/comments?post=2345"}],"version-history":[{"count":0,"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/posts\/2345\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/media?parent=2345"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/categories?post=2345"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/tags?post=2345"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}